DALLAS/FORT WORTH, Texas, March 17, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced financial results for the fourth quarter and 2015 fiscal year ended December 31, 2015.
“The past fifteen months have been incredibly exciting for Neos Therapeutics as we have worked towards our goal of providing more patient- and caregiver-friendly dosing options for the treatment of ADHD. With the January 2016 FDA approval of our first branded product, Adzenys XR-ODT, patients with ADHD will soon have access to the first and only extended-release orally disintegrating tablet (ODT) for the treatment of their condition,” said Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics. “This year, in addition to our launch of Adzenys XR-ODT, we are actively working to advance our late-stage product pipeline. If approved, these products would provide clinicians with a portfolio of treatment options for patients suffering from ADHD.”
